Orano Med was building something that did not exist yet at industrial scale.
Targeted alpha therapy using lead-212 to treat cancer. A new class of oncology drug requiring its own manufacturing, its own clinical trials, and its own regulatory path. The science was years ahead of the operating infrastructure behind it.
That gap showed up clearly in finance.
The US entity was running on Deltek Costpoint, with most of the actual accounting performed for them by an Orano shared services group in Virginia and Washington DC. They had no real control of their own books. Around Costpoint sat a layer of point tools and spreadsheets, scattered across reporting, consolidation, reconciliation, banking, invoice tracking, and budgets. The affiliate down in Plano was running on QuickBooks on a single workstation.
Each piece, on its own, was fine. Together, they did not add up to a system the finance team could actually run the business on.
The CFO in France decided it had to change. Genioo brought us in. We helped them evaluate their options, with a target to be live on a new platform in time for the next fiscal year.
They chose NetSuite. They chose Inscio to implement it.
Start where the visibility gap is widest.
We scoped a phased implementation around the work that would unlock the most control, the fastest.
SuiteSuccess Financials First gave them the GL, AR, AP, and close they had never owned. Advanced Financials added the project and allocation structures they needed to actually see where R&D dollars were going. Fixed Asset Management handled capital equipment tracking with the rigor their GMP and 21 CFR Part 11 environment required.
Two of the hardest pieces in life sciences finance were solved inside that first phase.
Separation of expenses across entities, projects, and partner contracts, so management could see what was actually being spent and where.
And clinical trial accounting, built on top of our Inscio Life Sciences Contract Tracker. It is a NetSuite-native clinical trial management solution that handles accounting, procurement, budgeting, and spend tracking across programs, contracts, and change orders. Initial funding tracked by trial. Vendor purchase orders aggregated by trial. Real approvals, workflows, tolerances, and change orders running against the work as it happened.
The team went live on time and under budget. The original plan held.
Go-live was the start, not the finish.
What followed was years of expansion on the same foundation.
Project management deepened. Automation came in. Supply chain modules came online. Then manufacturing, as Orano Med moved from research into producing therapies for clinical trials.
In the second year of the relationship, we brought Macrocyclics onto the same NetSuite instance. They had been running on QuickBooks on a single workstation. We rebuilt their inventory controls and supply chain inside NetSuite alongside Orano Med’s books, on the same platform. Then we built them a new website and connected it to NetSuite directly, so commerce, inventory, and finance moved as one system.
Two related entities. One platform. Manufacturing, distribution, ecommerce, clinical trials, and financial reporting all running together.
The visibility they came for, and the controls they did not yet know they needed.
When Orano Med first called, the request was straightforward. See our expenses. Run our own books. Have an opinion about our own financial reporting.
That happened.
What also happened, over time, was the discovery of how much more the same platform could do as the company grew into it. Procurement controls tightened. Approvals scaled cleanly as headcount grew. Manufacturing went live without anyone having to switch systems. A new website launched on top of the same data the finance team was closing the books with.
That is what the second-year case for NetSuite looks like in life sciences. Not a system you outgrow. A system that scales with you.
Running an R&D entity on a finance system built for someone else?
If your books are being kept on a parent company's platform, or stitched together across a layer of point tools, there is a cleaner way. Let's talk about what it could look like for you.
Schedule a Free Strategy Call